ROR2 and neoplasm: The Clinical Proteomic Tumor Analysis Consortium (CPTAC) Confirmation/Discovery cohort (n = 131)32 showed a significant reduction in expression of ROR2 as the tumour grade increased in EC (Supplementary Fig. S4).